Advertisement

Novel Oral Anticoagulants for the Prevention of Stroke in Patients with Atrial Fibrillation and Hypertension: A Meta-Analysis

  • Yayuan Zheng
  • Yuyu Liu
  • Jihong Bi
  • Weiguang Lai
  • Chunyu Lin
  • Jianhong ZhuEmail author
  • Weimin Yao
  • Qiusheng ChenEmail author
Original Research Article
  • 25 Downloads

Abstract

Introduction

Hypertension is associated with increased risk of stroke and bleeding in patients with atrial fibrillation (AF). In the present study, we aimed to investigate the influence of hypertension status in patients with AF receiving treatment with non-vitamin K antagonist oral anticoagulants (NOACs).

Methods

PubMed, Embase, and Cochrane Library were searched from the inception of each database to November 2017. Randomized controlled trials (RCTs) that evaluated NOACs versus warfarin in patients with AF and hypertension were identified. A meta-analysis was performed using random- or fixed-effects models according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.

Results

Five trials (72,967 patients, including 51,378 patients with hypertension) were enrolled. NOACs significantly reduced the risk of stroke and systemic embolism (hazard ratio [HR] 0.87, 95% confidence interval [CI] 0.81–0.94, n = 51,378 patients), hemorrhagic stroke (HR 0.55, 95% CI 0.41–0.74, n = 28,818 patients), death from any cause (HR 0.91, 95% CI 0.85–0.97, n = 43,101 patients), major bleeding (HR 0.78, 95% CI 0.74–0.83, n = 51,378 patients) and intracranial bleeding (HR 0.50, 95% CI 0.38–0.67, n = 27,185 patients). The benefits of NOACs in comparison with warfarin were consistent in AF patients with or without hypertension (Pinteraction for all outcomes > 0.05).

Conclusions

Our findings suggest that NOACs can be recommended for the prevention of stroke or systemic embolism in patients with AF and hypertension.

Notes

Acknowledgements

We acknowledge Dr. Robert P. Giugliano (Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, USA) for providing additional data and substantial support.

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of interest

Yayuan Zheng, Yuyu Liu, Jihong Bi, Weiguang Lai, Chunyu Lin, Jianhong Zhu, Weimin Yao and Qiusheng Chen declare that they have no potential conflicts of interest that might be relevant to the contents of this manuscript.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Informed consent

This article does not contain any studies with human participants or animals performed by any of the authors and no informed consent was needed.

Supplementary material

40256_2019_342_MOESM1_ESM.docx (20 kb)
Supplementary material 1 (DOCX 15 kb)

References

  1. 1.
    Chamberlain AM, Alonso A, Gersh BJ, Manemann SM, Killian JM, Weston SA, Byrne M, Roger VL. Multimorbidity and the risk of hospitalization and death in atrial fibrillation: a population-based study. Am Heart J. 2017;185:74–84.CrossRefGoogle Scholar
  2. 2.
    Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, Al-Khalidi HR, Ansell J, Atar D, Avezum A, Bahit MC, Diaz R, Easton JD, Ezekowitz JA, Flaker G, Garcia D, Geraldes M, Gersh BJ, Golitsyn S, Goto S, Hermosillo AG, Hohnloser SH, Horowitz J, Mohan P, Jansky P, Lewis BS, Lopez-Sendon JL, Pais P, Parkhomenko A, Verheugt FW, Zhu J, Wallentin L, ARISTOTLE Committees Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–92.CrossRefGoogle Scholar
  3. 3.
    Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, Waldo AL, Ezekowitz MD, Weitz JI, Špinar J, Ruzyllo W, Ruda M, Koretsune Y, Betcher J, Shi M, Grip LT, Patel SP, Patel I, Hanyok JJ, Mercuri M, Antman EM, ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–104.CrossRefGoogle Scholar
  4. 4.
    Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L, RE-LY Steering Committee Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–51.CrossRefGoogle Scholar
  5. 5.
    Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, Breithardt G, Halperin JL, Hankey GJ, Piccini JP, Becker RC, Nessel CC, Paolini JF, Berkowitz SD, Fox KA, Califf RM, ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–91.CrossRefGoogle Scholar
  6. 6.
    Verdecchia P, Angeli F, Reboldi G. Hypertension and atrial fibrillation: doubts and certainties from basic and clinical studies. Circ Res. 2018;122(2):352–68.CrossRefGoogle Scholar
  7. 7.
    Naser N, Dilic M, Durak A, Kulic M, Pepic E, Smajic E, Kusljugic Z. The impact of risk factors and comorbidities on the incidence of atrial fibrillation. Mater Sociomed. 2017;29(4):231–6.CrossRefGoogle Scholar
  8. 8.
    Borghi C, Paolillo S, Cicero AF, Gargiulo P, Trimarco B, Perrone Filardi P. New oral anticoagulants and prevention of thromboembolic events in patients with hypertension and atrial fibrillation: an appraisal. J Hypertens. 2017;35(4):689–95.CrossRefGoogle Scholar
  9. 9.
    Guzet F, Bitigen A, Karabay CY, Cimen AO, Teyfik N. Blood pressure control in anticoagulated hypertensive patients. Blood Press Monit. 2015;20(1):20–6.CrossRefGoogle Scholar
  10. 10.
    Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.CrossRefGoogle Scholar
  11. 11.
    Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1–12.CrossRefGoogle Scholar
  12. 12.
    Higgins JPT, Green S, Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Hoboken: Wiley; 2008.CrossRefGoogle Scholar
  13. 13.
    Rao MP, Halvorsen S, Wojdyla D, Thomas L, Alexander JH, Hylek EM, Hanna M, Bahit MC, Lopes RD, De Caterina R, Erol C, Goto S, Lanas F, Lewis BS, Husted S, Gersh BJ, Wallentin L, Granger CB, Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) Steering Committee and Investigators. Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial. J Am Heart Assoc. 2015;4(12):e002015.CrossRefGoogle Scholar
  14. 14.
    Nagarakanti R, Wallentin L, Noack H, Brueckmann M, Reilly P, Clemens A, Connolly SJ, Yusuf S, Ezekowitz MD. Comparison of characteristics and outcomes of dabigatran versus warfarin in hypertensive patients with atrial fibrillation (from the RE-LY trial). Am J Cardiol. 2015;116(8):1204–9.CrossRefGoogle Scholar
  15. 15.
    Vemulapalli S, Hellkamp AS, Jones WS, Piccini JP, Mahaffey KW, Becker RC, Hankey GJ, Berkowitz SD, Nessel CC, Breithardt G, Singer DE, Fox KA, Patel MR. Blood pressure control and stroke or bleeding risk in anticoagulated patients with atrial fibrillation: results from the ROCKET AF Trial. Am Heart J. 2016;178:74–84.CrossRefGoogle Scholar
  16. 16.
    Matsumoto M, Hori M, Tanahashi N, Momomura S, Uchiyama S, Goto S, Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iekushi K, Yamanaka S, Tajiri M. Rivaroxaban versus warfarin in Japanese patients with non-valvular atrial fibrillation in relation to hypertension: a subgroup analysis of the J-ROCKET AF trial. Hypertens Res. 2014;37(5):457–62.CrossRefGoogle Scholar
  17. 17.
    Figuera M, Cinza S, Egocheaga I, Marín N, Prieto MA, SILVER BRONCE-AP investigators. Clinical characteristics and management of patients with atrial fibrillation treated with direct oral anticoagulants according to blood pressure control. Hipertens Riesgo Vasc. 2018.  https://doi.org/10.1016/j.hipert.2018.01.003.Google Scholar
  18. 18.
    Hughes M, Lip GY. Risk factors for anticoagulation-related bleeding complications in patients with atrial fibrillation: a systematic review. QJM. 2007;100(10):599–607.CrossRefGoogle Scholar
  19. 19.
    Diener HC, Aisenberg J, Ansell J, Atar D, Breithardt G, Eikelboom J, Ezekowitz MD, Granger CB, Halperin JL, Hohnloser SH, Hylek EM, Kirchhof P, Lane DA, Verheugt FWA, Veltkamp R, Lip GYH. Choosing a particular oral anticoagulant and dose for stroke prevention in individual patients with non-valvular atrial fibrillation: part 2. Eur Heart J. 2017;38(12):860–8.Google Scholar
  20. 20.
    Kallistratos MS, Manolis AJ, Mancia G. The forgotten factor in previous and recent studies regarding anticoagulation in atrial fibrillation. Int J Cardiol. 2013;168:4434–5.CrossRefGoogle Scholar
  21. 21.
    Guzet F, Bitigen A, Karabay CY, Cimen AO, Teyfik N. Blood pressure control in anticoagulated hypertensive patients. Blood Press Monit. 2015;20:20–6.CrossRefGoogle Scholar
  22. 22.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Europace. 2016;18(11):1609–78.CrossRefGoogle Scholar
  23. 23.
    Patti G, Di Gioia G, Cavallari I, Nenna A. Safety and efficacy of nonvitamin K antagonist oral anticoagulants versus warfarin in diabetic patients with atrial fibrillation: a study-level meta-analysis of phase III randomized trials. Diabetes Metab Res Rev. 2017;33:e2876.CrossRefGoogle Scholar
  24. 24.
    Savarese G, Giugliano RP, Rosano GM, McMurray J, Magnani G, Filippatos G, Dellegrottaglie S, Lund LH, Trimarco B, Perrone-Filardi P. Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure: a meta-analysis. JACC Heart Fail. 2016;4(11):870–80.CrossRefGoogle Scholar
  25. 25.
    Caldeira D, David C, Costa J, Ferreira JJ, Pinto FJ. Non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease: systematic review and meta-analysis. Eur Heart J Cardiovasc Pharmacother. 2018;4(2):111–8.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2019

Authors and Affiliations

  1. 1.Laboratory of Physiological SciencesGuangdong Medical UniversityZhanjiangPeople’s Republic of China
  2. 2.Department of PharmacyGuangdong Medical UniversityZhanjiangPeople’s Republic of China
  3. 3.Department of PharmacyJin Xiang People’s HospitalDongyingPeople’s Republic of China
  4. 4.Department of Respiratory MedicineThe Affiliated Hospital of Guangdong Medical UniversityZhanjiangPeople’s Republic of China
  5. 5.Department of Pharmacy, Sun Yat-Sen Memorial HospitalSun Yat-Sen UniversityGuangzhouPeople’s Republic of China

Personalised recommendations